Strateos Appoints Biopharma Executive Tom Rush, PhD to its Scientific Advisory Board
MENLO PARK, Calif.–(BUSINESS WIRE)–#AI–Strateos, Inc., a pioneer in the development of remote access laboratories and lab control software for life science research, today announced the appointment of Tom Rush, PhD to the company’s Scientific Advisory Board.
“We are pleased to welcome Tom to our Scientific Advisory Board where his knowledge and passion for drug discovery will be invaluable as Strateos continues to bring new products to market and engage with biopharma R&D organizations,” said Mark Fischer-Colbrie, Chief Executive Officer at Strateos. “Tom has been a champion of driving efficiencies in the drug discovery process for decades and is an industry thought leader in the development of large-scale drug design and optimization platforms that leverage AI and complex datasets to help shorten the drug development timeline.”
Dr. Rush has more than 20 years of experience in discovering and developing therapeutics. He is currently the Chief R&D Officer at Variant Bio, where he leads the team that is translating human genetic findings into novel therapeutic targets, and then discovering and developing therapeutics that modulate them. He has also held leadership roles at GSK, Merck and Wyeth/Pfizer where he led programs focused on functional genomics, high-throughput biology and platform automation. Dr. Rush also served as the Chief Scientific Officer of the ATOM Consortium, a public-private initiative to accelerate the discovery and development of new therapeutics through a data driven, active learning and design platform. He holds a PhD in Physical Chemistry from the University of Oregon and was an NIH supported postdoctoral fellow at Princeton University.
“Drug discovery is rapidly becoming a technology-driven data science where high-throughput screening powered by AI and machine learning is required to make discoveries within an ever-mounting collection of genomic, biological, chemical, and phenotypic datasets,” said Dr. Rush. “Strateos has built one of the most advanced platforms to drive progress in drug discovery and a truly integrated data generation AI system driving closed loop iterative design cycles. I look forward to being an active advisor to the team as they re-imagine labs as smart data centers.”
Strateos is a pioneer in the development of remote access laboratories and lab control software for life science discovery. Our mission is to create new knowledge driven by data, computation, automation, and high-throughput robotics with the goal of fundamentally advancing the life sciences. The Strateos platform helps scientists more efficiently and reproducibly design, run, and analyze experiments to achieve new and faster scientific discoveries. For more information, please visit: www.strateos.com.